182 related articles for article (PubMed ID: 34253596)
1. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Mirzapoiazova T; Xiao G; Mambetsariev B; Nasser MW; Miaou E; Singhal SS; Srivastava S; Mambetsariev I; Nelson MS; Nam A; Behal A; Arvanitis LD; Atri P; Muschen M; Tissot FLH; Miser J; Kovach JS; Sattler M; Batra SK; Kulkarni P; Salgia R
Mol Cancer Ther; 2021 Oct; 20(10):1820-1835. PubMed ID: 34253596
[TBL] [Abstract][Full Text] [Related]
2. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
[TBL] [Abstract][Full Text] [Related]
4. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Hao S; Song H; Zhang W; Seldomridge A; Jung J; Giles AJ; Hutchinson MK; Cao X; Colwell N; Lita A; Larion M; Maric D; Abu-Asab M; Quezado M; Kramp T; Camphausen K; Zhuang Z; Gilbert MR; Park DM
Neuro Oncol; 2018 May; 20(6):799-809. PubMed ID: 29294092
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation.
Gao S; Shan L; Zhang M; Wang Y; Zhan X; Yin Y; Jiang Z; Tao X; Li X; Ye M; Liu Y
Cell Oncol (Dordr); 2022 Dec; 45(6):1203-1215. PubMed ID: 36136269
[TBL] [Abstract][Full Text] [Related]
6. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.
Hong CS; Ho W; Zhang C; Yang C; Elder JB; Zhuang Z
Cancer Biol Ther; 2015; 16(6):821-33. PubMed ID: 25897893
[TBL] [Abstract][Full Text] [Related]
7. Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Gordon IK; Lu J; Graves CA; Huntoon K; Frerich JM; Hanson RH; Wang X; Hong CS; Ho W; Feldman MJ; Ikejiri B; Bisht K; Chen XS; Tandle A; Yang C; Arscott WT; Ye D; Heiss JD; Lonser RR; Camphausen K; Zhuang Z
Mol Cancer Ther; 2015 Jul; 14(7):1540-1547. PubMed ID: 25939762
[TBL] [Abstract][Full Text] [Related]
8. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y
Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
[TBL] [Abstract][Full Text] [Related]
12. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
Wei D; Parsels LA; Karnak D; Davis MA; Parsels JD; Marsh AC; Zhao L; Maybaum J; Lawrence TS; Sun Y; Morgan MA
Clin Cancer Res; 2013 Aug; 19(16):4422-32. PubMed ID: 23780887
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX
Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035
[TBL] [Abstract][Full Text] [Related]
16. The effect of protein phosphatase 2A inhibitor LB100 on regulating methamphetamine induced conditioned place preference in mice.
Qian H; Wang J; Shang Q; Xiao J; Chen G; Gao B; Liang M; Li T; Liu X
Neurosci Lett; 2020 Mar; 721():134817. PubMed ID: 32032748
[TBL] [Abstract][Full Text] [Related]
17. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
18. Targeting PP2A for cancer therapeutic modulation.
Ronk H; Rosenblum JS; Kung T; Zhuang Z
Cancer Biol Med; 2022 Nov; 19(10):1428-39. PubMed ID: 36342229
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
20. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]